非小细胞肺癌中EML4-ALK融合基因的检测及临床意义

Detection and Clinical Significance of ALK Fusion Gene in Non-small Cell Lung Cancer

目的:为了对非小细胞肺癌的治疗提供参考依据,分析ALK融合基因的检测及临床意义。方法:根据随机原则的相关要求从2015年1月-2018年6月在笔者所在医院治疗的非小细胞肺癌患者中抽取60例作为研究对象,所有患者均通过二代测序技术(NGS)检测病理标本中的EML4-ALK融合基因,探讨EML4-ALK融合基因表达与各病理特征及临床指标的关系。结果:研究数据显示,60例患者中EML4-ALK融合基因阳性表达率为13.33%(8/60),而且阳性表达率在病理组织类型、既往吸烟史及肿瘤分化程度间比较差异有统计学意义(P<0.05)。结论:在非小细胞肺癌患者中EML4-ALK融合基因存在过度表达的情况,这与肿瘤的发生、发展密切相关,临床应重视对其检测。

Objective:To provide reference for the treatment of non-small cell lung cancer,and to analyze the detection and clinical significance of EML4-ALK fusion gene.Method:According to the relevant requirements of random principle,60 patients with non-small cell lung cancer treated in our hospital from January 2015 to June 2018 were selected as the research subjects.All patients were detected ALK fusion gene in pathological specimens by second generation sequencing(NGS),and the relationship between ALK fusion gene expression and pathological characteristics and clinical indicators was discussed.Result:The data showed that the positive expression rate of ALK fusion gene was 13.33%(8/60) in 60 patients,and there were significant differences in histopathological type,smoking history and tumor differentiation(P<0.05).Conclusion:Overexpression of ALK fusion gene exists in NSCLC patients,which is closely related to the occurrence and development of tumors.Clinical detection of ALK fusion gene shall be emphasized.